Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD

 An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (...
Continue reading

First CAR T-Cell Therapy Approved for Mantle Cell Lymphoma

The FDA has now granted accelerated approval to brexucabtagene autoleucel (TecartusTM, Kite Pharma, formerly known as KTE-X19) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL). Brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is the first CAR T-cell therapy approved for this rare type of B-cell non-Hodgkin lymphoma. Efficacy was evaluated in the multicenter, open-label phase 2 ZUMA-2 trial (NCT02601313), which enrolled 7...
Continue reading

Zanubrutinib Approved for Mantle Cell Lymphoma

The FDA has approved zanubrutinib (Brukinsa®, BeiGene) for patients with relapsed/refractory mantle cell lymphoma (MCL) who have received at least one previous therapy. The approval was based on two clinical trials. BGB-3111-206, a single-arm phase 2 trial, enrolled 86 patients with MCL whose disease progressed following at least one prior therapy. Patients received 160 mg of zanubrutinib orally twice daily until unacceptable toxicity or disease progression. The study's primary end point was ove...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright ┬ę 2021 Oncology Data Advisor. All rights reserved.